Evelyn Partners Investment Management LLP Reduces Stock Holdings in Stryker Corporation $SYK

Evelyn Partners Investment Management LLP lowered its holdings in shares of Stryker Corporation (NYSE:SYK) by 0.7% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 265,451 shares of the medical technology company’s stock after selling 1,863 shares during the quarter. Stryker makes up approximately 2.4% of Evelyn Partners Investment Management LLP’s holdings, making the stock its 11th biggest position. Evelyn Partners Investment Management LLP owned about 0.07% of Stryker worth $87,225,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in SYK. Vanguard Group Inc. grew its position in Stryker by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock valued at $11,917,396,000 after buying an additional 133,892 shares during the period. State Street Corp raised its position in Stryker by 2.1% in the fourth quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock worth $5,374,731,000 after acquiring an additional 311,507 shares during the period. Geode Capital Management LLC boosted its stake in shares of Stryker by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock worth $2,636,238,000 after acquiring an additional 69,851 shares during the last quarter. Wellington Management Group LLP grew its position in shares of Stryker by 22.6% during the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after acquiring an additional 1,198,665 shares during the period. Finally, Norges Bank bought a new stake in shares of Stryker during the 4th quarter valued at $1,822,272,000. Institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 5,220 shares of the business’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the sale, the vice president owned 13,137 shares in the company, valued at approximately $3,728,937.45. The trade was a 28.44% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 323,264 shares of company stock worth $100,659,489. 4.60% of the stock is owned by insiders.

Stryker Stock Performance

NYSE:SYK opened at $337.31 on Tuesday. The stock has a 50-day moving average price of $315.18 and a 200 day moving average price of $335.37. The stock has a market capitalization of $129.31 billion, a P/E ratio of 39.04, a P/E/G ratio of 2.12 and a beta of 0.77. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $404.14. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. During the same period in the prior year, the firm posted $2.84 earnings per share. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities research analysts forecast that Stryker Corporation will post 14.99 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s payout ratio is 40.74%.

Analysts Set New Price Targets

A number of research firms have recently weighed in on SYK. Wells Fargo & Company lowered their price objective on Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Truist Financial restated a “hold” rating and set a $330.00 target price (down from $380.00) on shares of Stryker in a research note on Monday, May 4th. Leerink Partners lowered their price target on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a report on Friday, June 5th. Citigroup reduced their price objective on shares of Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research note on Tuesday, April 7th. Finally, Sanford C. Bernstein set a $410.00 price objective on shares of Stryker in a research report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $392.52.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.